VisMederi Holding
Improving human health
Vismederi Holding
Vismederi Holding is the company that holds a qualified share of the companies that are part of the VisMederi Group. The Group of Vismederi Holding operates in various business areas all related to Research and Innovation in the fields of Public Health, Life Sciences and Biotechnologies and is composed of VisMederi Srl, VisMederi Research Srl, VisMederi Life Sciences Srl, VisMederi Textyle Srl, VisMederi Pharma Srl, ETHS – Education and Training for Health Sciences Srl with single shareholder, Accurange Srl.
Revenues
Employees
Global Partnerships
Vismederi Holding: last news
All the news of the group
Making Strides in Global Health: VisMederi at the World Bio Summit 2023!
VisMederi reaffirms its position as a “Growth Leader”
GBA Roadshow 2023
Project Leader Silvia Grappi represented VisMederi at the 11th EDTCP meeting in Paris
VisMederi Foundation with “Ragazzi del ‘53” in support of “Le Bollicine” Association
Another remarkable milestone in our journey of scientific collaboration
VisMederi Foundation: Continuing its Commitment to Social Welfare by Supporting Piccolo Principe and Danilo Nannini Foundation
VisMederi Receives Prestigious Certificate from The Coalition for Epidemic Preparedness Innovations (CEPI)
Neutralizing antibody responses against the Respiratory Syncytial Virus
VisMederi Takes the Lead in Assessing Safety and Immunogenicity of Yellow Fever Vaccine
Where we
are
The
founder
Emanuele Montomoli is Full Professor of Hygiene and Public Health at the University of Siena, Italy. He received his BSc and MSc in Life Sciences from the University of Siena, Italy in 1997 and he earned his MBiochem in 2001.
VisMederi is at the World Vaccine Congress West Coast, California.
Chief Development Officer Alessandro Manenti, Project Director Luisa Ganfini, and Prof. Nigel Temperton from the University of Kent are attending the World Vaccine Congress West Coast in California to explore innovative vaccine platforms and further improve international collaboration.
*******
Il Chief Development Officer Alessandro Manenti, la project director Luisa Ganfini e il Prof. Nigel Temperton dell'Università di Kent partecipano al World Vaccine Congress West Coast in California per esplorare piattaforme vaccinali innovative e migliorare ulteriormente la collaborazione internaziona#vismederigroupg#healthcareinnovationa#wvcwcW#worldvaccinecongressg#vaccinesc#vaccineinnovationa#healthcarehcare ... See MoreSee Less
0 CommentsComment on Facebook
Congratulations to Carolina Bonifazi, Project Director at VisMederi, on earning her Master's Degree Ph.D. in Life Sciences from the University of Siena!
This achievement is not just a personal milestone but also a testament to the strong and fruitful partnership between VisMederi and the University of Siena. From all of us at VisMederi, we extend our heartfelt congratulations to Caroli#teamvismederie#vismederisuccessc#UniversityOfSienaS#vismederigroupgroup
******
Congratulazioni a Carolina Bonifazi, Project Director a VisMederi, per aver conseguito il Dottorato di Ricerca in Scienze della Vita presso l'Università di Siena!
Questo traguardo non è solo un traguardo personale, ma anche una testimonianza della forte e fruttuosa partnership tra VisMederi e l'Università di Siena.
Da tutti noi di VisMederi, esprimiamo le nostre più sincere congratulazion#vismederin#dottoratodiricercat#ScienzedellaVitacienzedellavita ... See MoreSee Less
0 CommentsComment on Facebook
VisMederi has been featured in the special "Growth Leader 2024" list for the second year in a row, a distinguished excellence awarded by "Sole 24 Ore” and “Statista."
This award honors the 500 Italian companies having the best sales growth during the three-year period 2019-2022. VisMederi was placed second in the "Pharmaceuticals and Biotechnology" category and 84th out of overall.
We are proud and we thank all of the staff that helped VisMederi achieve this result!
°°°°°°°
VisMederi è stata inserita per il secondo anno consecutivo nella speciale classifica "Leader della crescita 2024", un'eccellenza premiata dal "Sole 24 Ore" e da "Statista".
Il riconoscimento premia le 500 aziende italiane con la migliore crescita del fatturato nel triennio 2019-2022. VisMederi si è classificata al secondo posto nella categoria "Farmaceutica e Biotecnologie" e all'84° posto in assoluto.
Siamo orgogliosi e ringraziamo tutto lo staff che ha aiutato VisMederi a raggiungere questo importante risultato!
#LeaderDellaCrescita #VisMederi #VisMederiGroup #Sole24Ore #Siena ... See MoreSee Less
0 CommentsComment on Facebook
Making Strides in Global Health: VisMederi at the World Bio Summit 2023!
VisMederi, represented by the Founder and CSO Prof. Emanuele Montomoli, played a pivotal role at the esteemed World Bio Summit 2023 in Seoul.
This landmark event united over 200 luminaries, from government officials to biopharma leaders, to forge paths in pandemic preparedness and response.
Hosted jointly by the Ministry of Health and Welfare, IVI, CEPI and the WHO, the summit focused on emerging health challenges, highlighting the essential role of diagnostics and vaccines in pandemic management.
#worldbiosummit2023 #globalhealth #pandemicpreparedness #cepi #healthinnovation #TogetherForHealth #vismederigroup
°°°°°°°
Passi avanti nella salute globale: VisMederi al World Bio Summit 2023!
VisMederi, rappresentata dal Fondatore e CSO Prof. Emanuele Montomoli, ha svolto un ruolo fondamentale all'apprezzato World Bio Summit 202#seoulSeoul.
Questo evento di riferimento ha riunito oltre 200 luminari, da funzionari governativi a leader del settore biofarmaceutico, per forgiare percorsi di preparazione e risposta alle pandemie.
Ospitato congiuntamente dal Ministero della Salute e del Welfare, dall'IVI, dal CEPI e dall'OMS, il summit si è concentrato sulle sfide sanitarie emergenti, evidenziando il ruolo essenziale della diagnostica e dei vaccini nella gestione de#vismederii#gestionepandemiee#diagnosticai#worldbiosummit2023ldbiosummit2023
WorldBio Summit ... See MoreSee Less
0 CommentsComment on Facebook